Huashan hospital Fudan University
Shanghai, Shanghai Municipality, 200040, China
Location status: Recruiting
NCT Number: NCT07171242
This study aims to conduct a prospective cohort study on patients with imaging-confirmed ischemic stroke based on the 4S database. The primary objectives are to investigate the incidence, clinical characteristics, risk factors, and pathophysiological mechanisms of young-onset stroke, as well as to analyze the evolving trends in the etiology of young-onset stroke in the Shanghai region over recent years. This includes examining the roles of traditional risk factors (such as hypertension and diabetes) and emerging factors (such as air pollution and lifestyle changes), and exploring the associations between these factors and patient outcomes. Additionally, the study will analyze the association between reperfusion therapies such as intravenous thrombolysis, acute-phase management, and secondary prevention with clinical outcomes. Finally, it will delve into the screening, treatment, and challenges associated with genetic young stroke patients with Farby syndrome, providing comprehensive information for regional stroke prevention and control strategies targeting young stroke patients.
Interested in participating?
Request Info18 year and older
All sexes
Observational
Shanghai, Shanghai Municipality, 200040, China
Location status: Recruiting
This study is designed as a prospective cohort investigation utilizing data from the 4S database, focusing specifically on patients with imaging-confirmed ischemic stroke who are classified as having young-onset stroke (typically defined as occurring in individuals under 55 years of age). The purpose is to provide a thorough understanding of stroke in younger populations within the Shanghai region through collecting relevant clinical information of patients.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: Upon admission
Name, age, gender, place of residence, date of admission, name of hospital, hospital grade, TOAST classification
Time frame: Upon admission
The presence (Yes) or absence (No) of each listed risk factor will be determined for each participant through medical history review and clinical evaluation:Smoking, hypertension, atrial fibrillation, hyperlipidemia, diabetes, history of cerebral infarction, myocardial infarction, other heart diseases, dementia, chronic obstructive pulmonary disease, history of bleeding or bleeding tendency
Time frame: Upon admission
The use of the following pre-illness medication categories, as confirmed by medical history review upon admission, will be recorded as a binary outcome (Yes/No) for each participant: antihypertensive drugs, antidiabetic drugs, lipid-lowering drugs, anticoagulants, antiplatelet drugs.
Time frame: Upon admission
The severity of neurological deficit will be assessed using the National Institutes of Health Stroke Scale (NIHSS) upon admission. The NIHSS is a 15-item neurologic examination stroke scale with scores ranging from 0 to 42, where higher scores indicate more severe neurological deficit.
Time frame: Prior to stroke admission (assessed upon current admission)
Functional ability prior to stroke admission will be assessed using the Modified Rankin Scale (mRS). The mRS is a 6-point disability scale ranging from 0 (no symptoms) to 5 (severe disability), with a separate score of 6 indicating death. Higher scores indicate worse functional outcome.
Time frame: Upon admission
The following time points will be recorded to determine delays in presentation: time when the patient was last known to be at their normal neurological baseline, time of symptom onset, and time of arrival at the hospital.
Time frame: Within 24 hours of admission
The administration of specific reperfusion therapies during hospitalization will be recorded as a binary outcome (Yes/No) for each participant. Therapies include: intravenous thrombolysis and endovascular treatment (mechanical thrombectomy). Determination will be made through review of medical records and procedure documentation.
Time frame: At admission (within 24 hours of hospitalization)
The presence of findings on baseline neuroimaging (CT or MRI) performed at admission will be recorded. This includes the presence of cerebral small vessel disease manifestations (e.g., white matter hyperintensities, lacunes) and the location and degree of large vessel occlusion/stenosis.
Time frame: Within 7 days of admission
Results from cardiac evaluations performed during hospitalization will be recorded as binary outcomes (normal/abnormal). Assessments include: echocardiogram (cardiac ultrasound), electrocardiogram (ECG), 24-hour Holter monitoring, and bubble test (for patent foramen ovale detection).
Time frame: Day 7 post-stroke (or at discharge if earlier)
Functional outcome at discharge will be assessed using the Modified Rankin Scale (mRS). The mRS is a 7-point disability scale ranging from 0 (no symptoms) to 6 (death), where higher scores indicate worse functional outcome.
Time frame: Day 7 post-stroke (or at discharge if earlier)
The primary diagnosis documented in the medical record at the time of hospital discharge will be recorded.
Time frame: Up to 30 days (from admission to discharge,this will be calculated from admission to discharge for each participant)
The duration of hospitalization, calculated as the number of days from admission to discharge.
Contact information is provided by the study sponsor or research team.
Qiang Dong
Other
Acronym: 4S
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07345702
Basilar Artery Occlusion, Brain Diseases
Beijing, Beijing Municipality, China
View Trial DetailsNCT05032053
Brain Diseases, Cardiovascular Diseases
Ankang, Shaanxi, China
View Trial DetailsNCT07736885
Brain Diseases, Cardiovascular Diseases
Tianjin, Tianjin Municipality, China
View Trial DetailsNCT07731087
Brain Diseases, Cardiovascular Diseases
Makassar, South Sulawesi, Indonesia
View Trial Details